Sustained small interfering RNA delivery by mesoporous silicon particles.

RNA interference (RNAi) is a powerful approach for silencing genes associated with a variety of pathologic conditions; however, in vivo RNAi delivery has remained a major challenge due to lack of safe, efficient, and sustained systemic delivery. Here, we report on a novel approach to overcome these limitations using a multistage vector composed of mesoporous silicon particles (stage 1 microparticles, S1MP) loaded with neutral nanoliposomes (dioleoyl phosphatidylcholine, DOPC) containing small interfering RNA (siRNA) targeted against the EphA2 oncoprotein, which is overexpressed in most cancers, including ovarian. Our delivery methods resulted in sustained EphA2 gene silencing for at least 3 weeks in two independent orthotopic mouse models of ovarian cancer following a single i.v. administration of S1MP loaded with EphA2-siRNA-DOPC. Furthermore, a single administration of S1MP loaded with-EphA2-siRNA-DOPC substantially reduced tumor burden, angiogenesis, and cell proliferation compared with a noncoding control siRNA alone (SKOV3ip1, 54%; HeyA8, 57%), with no significant changes in serum chemistries or in proinflammatory cytokines. In summary, we have provided the first in vivo therapeutic validation of a novel, multistage siRNA delivery system for sustained gene silencing with broad applicability to pathologies beyond ovarian neoplasms.

[1]  W. Freeman,et al.  Porous silicon in drug delivery devices and materials. , 2008, Advanced drug delivery reviews.

[2]  W. Oyen,et al.  Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. , 2001, The Journal of pharmacology and experimental therapeutics.

[3]  R. Schilsky,et al.  A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[5]  Peter W. Swaan,et al.  Microfabricated Porous Silicon Particles Enhance Paracellular Delivery of Insulin Across Intestinal Caco-2 Cell Monolayers , 2004, Pharmaceutical Research.

[6]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[7]  A. Lane,et al.  Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. , 1998, Genes & development.

[8]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[9]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[10]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[11]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[12]  J. Rhim,et al.  Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway , 2001, Nature Cell Biology.

[13]  D. Harpole,et al.  Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[15]  A. Loni,et al.  Mesoporous silicon: a platform for the delivery of therapeutics , 2007, Expert opinion on drug delivery.

[16]  D. Gandara,et al.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[18]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[19]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[20]  Liz Y. Han,et al.  EphA2 overexpression is associated with angiogenesis in ovarian cancer , 2007, Cancer.

[21]  Santhosh K. P. Kumar,et al.  The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. , 2006, Blood.

[22]  L. Canham.  Bioactive silicon structure fabrication through nanoetching techniques , 1995 .

[23]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[24]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[25]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[26]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[27]  J. Rossi,et al.  Sensing the danger in RNA , 2005, Nature Medicine.

[28]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[29]  Benjamin L Miller,et al.  Enzyme immobilization in porous silicon: quantitative analysis of the kinetic parameters for glutathione-S-transferases. , 2005, Analytical chemistry.

[30]  M. Herlyn,et al.  Up‐regulation of ephrin‐a1 during melanoma progression , 1999, International journal of cancer.

[31]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[32]  G. Yancopoulos,et al.  Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. , 2002, Molecular cancer research : MCR.

[33]  T. Anchordoquy,et al.  In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. , 2008, Journal of pharmaceutical sciences.

[34]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[35]  Haibin Xia,et al.  siRNA-mediated gene silencing in vitro and in vivo , 2002, Nature Biotechnology.

[36]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.

[37]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[38]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[39]  L. Canham,et al.  Complete Tumor Response Following Intratumoral 32P BioSilicon on Human Hepatocellular and Pancreatic Carcinoma Xenografts in Nude Mice , 2005, Clinical Cancer Research.

[40]  Anil K Sood,et al.  Therapeutic Targeting of ATP7B in Ovarian Carcinoma , 2009, Clinical Cancer Research.

[41]  Jennifer L. Cutter,et al.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. , 2009, Cancer cell.

[42]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[43]  A. Sood,et al.  Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors , 2005, Clinical Cancer Research.

[44]  Mauro Ferrari,et al.  Adhesion of Microfabricated Particles on Vascular Endothelium: A Parametric Analysis , 2004, Annals of Biomedical Engineering.

[45]  A. Gewirtz,et al.  Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. , 2009, The Journal of clinical investigation.

[46]  P. Low,et al.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Sood,et al.  EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. , 2009, Journal of the National Cancer Institute.

[48]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[49]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[50]  B. Tycko,et al.  Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation , 2002, Molecular Cancer.